Event Set for November 4-7 at Town and Country Resort, San Diego
Fueled by Enhertu’s tumor-agnostic accelerated approval, practice changing PADCEV combination results, a frenzy of companies entering the field, and rampant billion-dollar partnerships and M&As from Pfizer, AbbVie, J&J, Merck, Genmab, Ipsen and beyond; ADCs have firmly positioned themselves at the forefront of oncology R&D and dealmaking.
World ADC San Diego, the world’s longest-standing and definitive forum for Antibody-Drug Conjugates (ADC), is returning for its 15th anniversary in just a few weeks’ time. This year’s event promises groundbreaking content, engaging discussions, and networking opportunities for professionals across the ADC community, from novices to seasoned experts.
Event highlights include:
Brand-new Presenting Biopharma: With the largest speaker faculty to date, learn from first-time presenting biotechs ABL Bio, Angiex, Huadong Medicine, Multitude Therapeutics, Mythic Therapeutics, and Oxford Biotherapeutics; and oncology leaders from big pharma on the scene Pfizer, Ipsen, and AbbVie showcasing their latest work and insights in ADC development.
End-to-end Insights from Bench to Bedside streamlined into 6 tracks of scientific content: discovery chemistry, cellular biology, translation, clinical lessons, process and analytical development, manufacturing and supply chain. With content for everyone on your team, attendees can expect to receive unparalleled knowledge across cutting-edge R&D, end-to-end development strategy, and global market trends.
Brand-new Pharmacology Seminar Day: This brand-new seminar stream is designed for ADC experts working in PK/PD and clinical pharmacology to explore ADC PD markers and modeling, early clinical dose optimization and best practices for ADC pharmacology strategy to inform successful ADC clinical performance.
Unrivaled Structured Networking: As the ADC community is reunited all under one roof, there will be multiple networking opportunities with fellow ADC enthusiasts across the scientific poster session, breakfast briefings, lunch and learns, drinks receptions and the prestigious 11th World ADC Awards to renew and establish long-lasting scientific and commercial relationships.
There is no therapeutic modality generating as much excitement as ADCs, and no conference demonstrates their potential like World ADC San Diego. As THE annual touchpoint for the scientific community, participants can look forward to a melting pot of innovation, collaboration, and inspiration to progress ADC development to new standard of care treatments in oncology and beyond.
For more information, including registration details and the full event agenda, please visit www.worldadc-usa.com.
